A genetically modified herpes virus was effective in fighting skin cancer by infecting and destroying cancer cells as well as triggering an immune response, according to results of a clinical trial released on Tuesday.
It was the first time an advanced-stage trial of this type of drug has shown such positive results, according to scientists from The Institute of Cancer Research in London who published their study in the American Journal of Clinical Oncology.
The dramatic results, showing a large jump in survival length, could lead the drug T-VEC (Talimogene Laherparepvec) to be approved by US and European drug regulators.
Researchers randomly selected 436 patients with inoperable advanced melanoma to receive an injection of T-VEC made by US company Amgen.
The Reopen America Back to School Special is now live! Earn double Patriot Points on our hottest items!